The Latest Breaking News from Guardant Health

Guardant Health stock jumped Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.

At a time when colorectal cancer is rising, researchers say a blood test can detect 83% of people with the disease. If the FDA approves it the test would be another screening tool for early detection.

Learn about promising advancements in colon cancer screening methods, including new blood tests and improved stool tests, offering hope for increased early...

Many AI techniques are already being used in healthcare, where the highest degree of accuracy is required. One such area is oncology testing and the cancer research programs of Guardant Health.

Guardant Health sees its Relative Strength Rating enter the 80-plus level.

Guardant Health shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.

Over the past 3 months, 6 analysts have published their opinion on Guardant Health (NASDAQ:GH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.